Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00011-008-7210-y
Title: Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis
Authors: Bhatia, M. 
Landolfi, C.
Basta, F.
Bovi, G.
Ramnath, R.D. 
De Joannon, A.C.
Guglielmotti, A.
Keywords: Bindarit
Colitis
Inflammation
MCP-1
TNBS
Issue Date: Oct-2008
Source: Bhatia, M., Landolfi, C., Basta, F., Bovi, G., Ramnath, R.D., De Joannon, A.C., Guglielmotti, A. (2008-10). Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. Inflammation Research 57 (10) : 464-471. ScholarBank@NUS Repository. https://doi.org/10.1007/s00011-008-7210-y
Abstract: Objective: Chemokines play a fundamental role in trafficking and activation of leukocytes in colonic inflammation. We investigated the ability of bindarit, an inhibitor of monocyte chemoattractant protein-1 (MCP-1/CCL2) synthesis, to inhibit chemokine production by human intestinal epithelial cells (HT-29) and its effect in trinitro-benzene sulfonic acid (TNBS)-induced colitis in mice. Materials and Methods: HT-29 cells were incubated with bindarit in the presence of TNF-α/IFN-γ and 24 h later supernatants were collected for MCP-1, IL-8 and RANTES measurement. A 1 mg enema of TNBS was given to BALB/c mice, and bindarit (100 mg/kg) was orally administered twice daily starting from two days before colitis induction. Weight loss, histology, and MCP-1 level and myeloperoxidase (MPO) activity in colon extracts were assessed. Results: In HT-29 cells, bindarit concentration-dependently and selectively inhibited MCP-1 secretion (as well as mRNA expression) primed by TNF-α/IFN-γ. Moreover treatment with bindarit reduced clinical and histopathological severity of TNBS-induced colitis. These effects were associated with significant inhibition of MCP-1 and MPO in colon extracts. Conclusions: Bindarit exhibits a potent bioactivity in reducing leukocyte infiltration, down-regulating MCP-1 synthesis, and preventing the development of severe colitis in a mice model of TNBS-induced colitis. These observations suggest a potential use of MCP-1 synthesis blockers in intestinal inflammation in humans. © 2008 Birkhäuser Verlag.
Source Title: Inflammation Research
URI: http://scholarbank.nus.edu.sg/handle/10635/130085
ISSN: 10233830
DOI: 10.1007/s00011-008-7210-y
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

22
checked on Feb 13, 2018

WEB OF SCIENCETM
Citations

17
checked on Feb 13, 2018

Page view(s)

9
checked on Feb 20, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.